Neuropeptides: What They Are and How They Were Identified
For laboratory research use only. The compounds discussed here are sold strictly for in vitro research. They are not drugs, supplements or cosmetics and are not for human or animal use. This article summarizes published literature for reference and is not medical or usage advice.
Neuropeptides are short amino acid chains that neurons release to talk to other cells, and the field that studies them keeps getting caught off guard. Enkephalin turned up because people were chasing whatever natural molecule the opiate receptor was built for. Ghrelin turned up the other way round, from a receptor sitting there with no known ligand. Orexin came out of an orphan receptor screen. Same story each time: the molecule appears, and the pharmacology gets rebuilt around it afterwards. Below: what counts as a neuropeptide, how the famous ones were pinned down, and why we pay more attention to the receptor than to the peptide.
Key findings
- 1975: two pentapeptides, Tyr-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu, sequenced by dansyl-Edman and mass spectrometry, then synthesised and matched against the natural material [1].
- The oxytocin receptor is a class I GPCR, Gq to phospholipase C-beta, and it needs both Mg2+ and cholesterol to reach its high-affinity state [2].
- Orexin-A and orexin-B are cut from one precursor and activate two closely related receptors, both orphans until 1998 [3].
- Ghrelin: 28 residues, octanoyl group on serine 3, and strip that acyl group off and the activity goes with it [4].
- Its receptor, GHS-R1a, was cloned in 1996, a full three years ahead of the ligand [5].
- Size predicts nothing. A pentapeptide and a 28-mer can both be potent at their targets [1][4].
So what counts as a neuropeptide
Two features, really. It is made as part of a larger precursor protein and cut out by processing enzymes, and it is released by neurons to act on receptors, usually G protein coupled ones. The orexin paper is a tidy illustration: orexin-A and orexin-B are both carved from a single precursor by proteolytic processing, then bind two related receptors [3].
Length varies wildly and tells you almost nothing. Enkephalins are five residues [1]. Ghrelin is 28, cleaved from a 117 residue precursor [6]. Both are potent at their targets. The old habit of sorting peptides by residue count, oligopeptides here, polypeptides there, is a chemistry convention that predicts nothing about signalling.
Post-translational modification can matter far more than size. Ghrelin without its serine 3 octanoyl group does not do the job, which Kojima’s group established in the paper that named it [4]. That is one acyl chain deciding whether a 28 residue peptide is active or inert.
Four discoveries worth knowing
Enkephalins, 1975
Hughes, Kosterlitz and colleagues isolated material from brain with opiate agonist activity and sequenced it by the dansyl-Edman procedure and mass spectrometry, then synthesised both pentapeptides and compared them against the natural material [1]. Isolate, sequence, synthesise, compare. Fifty years later that is still the template for proving a peptide’s identity.
Oxytocin’s receptor, characterised over decades
Oxytocin itself is old news, a nine residue neurohypophysial peptide. Its receptor is where the pharmacology lives. Gimpl and Fahrenholz’s review lays out a class I GPCR coupling mainly through Gq proteins to phospholipase C-beta, with high-affinity binding dependent on Mg2+ and cholesterol acting as allosteric modulators, and an agonist binding region distinct from the antagonist site [2]. The receptor is expressed well beyond the brain, including in kidney, heart, thymus, pancreas and adipocytes.
Orexins, 1998
Sakurai and colleagues reported two new peptides from one precursor, binding two previously orphan G protein coupled receptors [3]. This is reverse pharmacology: the receptor sequence arrived first, and the ligand was hunted afterwards.
Ghrelin, 1999
Same pattern, different tissue. Howard’s group cloned GHS-R1a from pituitary and hypothalamus in 1996 and noted the receptor implied an undiscovered hormone [5]. Kojima’s group purified that hormone from rat stomach three years later [4], and IUPHAR formalised the naming afterwards, renaming the receptor after its ligand [6].
| Peptide | Length | Receptor class | Identified |
|---|---|---|---|
| Met- and Leu-enkephalin | 5 residues [1] | Opioid receptors | 1975 [1] |
| Oxytocin | 9 residues | Class I GPCR, Gq to PLC-beta [2] | Receptor system reviewed 2001 [2] |
| Orexin-A and orexin-B | From one precursor [3] | Two related GPCRs [3] | 1998 [3] |
| Ghrelin | 28 residues, octanoylated Ser3 [4] | GHS-R1a, class A GPCR [5][6] | 1999 [4] |
Synthetic analogues of natural fragments
A large slice of the synthetic peptide literature is not about natural neuropeptides at all. It is about short fragments of them with modifications bolted on. Semax is the ACTH(4-7) fragment plus a Pro-Gly-Pro tail, and in rats it altered Bdnf and Ngf expression within an hour, upward in hippocampus, downward for Ngf in frontal cortex [7]. Selank takes the same Pro-Gly-Pro approach on tuftsin, an immunoglobulin-derived tetrapeptide [8].
And here is the catch with that whole class. Neither one has a characterised receptor in the published work. What you get instead is downstream stuff, gene expression, tissue content, behavioural scores, and never a binding curve at a named target. We read those papers with that gap in mind, which is not how we read a ghrelin or oxytocin paper. Our Selank overview and our Selank and Semax comparison go into both sequences in detail.
How to read a neuropeptide paper
Four questions sort most of the noise out.
Which receptor, and was it identified or assumed? A cloned receptor with binding data is a different class of evidence from an inferred mechanism. Compare the ghrelin line of work [5] against the synthetic fragments above.
What was measured? Transcript levels are not protein levels, and protein content is not release. The Semax neurotrophin study reports mRNA by real-time PCR, which is exactly what it says it is and nothing more [7].
In what system? Cultured cells, rodent tissue and human volunteers answer different questions, and a result does not travel between them for free.
Is the modification state specified? For acylated peptides this is decisive, as the ghrelin octanoylation requirement shows [4]. A paper that does not say which form it used has left a hole in its methods.
Characterisation of synthetic material
The analytical baseline does not change from peptide to peptide. Reversed phase HPLC gives you a chromatographic purity figure for one batch, one run. Mass spectrometry checks the molecular mass against the sequence you expect, and it is what catches a missing acyl group or an acetylation nobody asked for. Neither number means much alone, which is why a certificate pairs them with a batch identifier and a date. Ours are posted at wholesalepeptide.com/coas, every batch is tested by a U.S.-based third-party laboratory, and there is more detail on our third-party testing page.
References
- Hughes J, Smith TW, Kosterlitz HW, et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975. PMID 1207728
- Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001. PMID 11274341
- Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors. Cell. 1998. PMID 9491897
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PMID 10604470
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996. PMID 8688086
- Davenport AP, Bonner TI, Foord SM, et al. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005. PMID 16382107
- Agapova TY, Agniullin YV, Shadrina MI, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neurosci Lett. 2007. PMID 17353092
- Kolik LG, Nadorova AV, Antipova TA, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019. PMID 31625062